Comparative Pharmacology
Head-to-head clinical analysis: SULFADIAZINE SODIUM versus UROPLUS SS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SULFADIAZINE SODIUM versus UROPLUS SS.
SULFADIAZINE SODIUM vs UROPLUS SS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sulfadiazine is a competitive inhibitor of dihydropteroate synthase, blocking the conversion of p-aminobenzoic acid (PABA) to dihydropteroate, thereby inhibiting bacterial folic acid synthesis.
Uroplus SS contains sulfamethoxazole and trimethoprim. Sulfamethoxazole inhibits bacterial dihydrofolic acid synthesis by competing with para-aminobenzoic acid (PABA) for dihydropteroate synthase. Trimethoprim inhibits bacterial dihydrofolate reductase, blocking reduction of dihydrofolate to tetrahydrofolate. The sequential blockade of folic acid metabolism produces bactericidal activity.
2-4 g IV initially, then 1-2 g IV every 6-8 hours; oral dose: 2-4 g loading, then 1-2 g every 6 hours
4 grams orally once daily as a single dose or in divided doses for 10 to 14 days for urinary tract infections.
None Documented
None Documented
Terminal elimination half-life: 10-20 hours (prolonged in renal impairment; context: requires dose adjustment in CrCl <50 mL/min).
Terminal elimination half-life is 18–24 hours, allowing once-daily dosing; steady-state achieved in 3–5 days.
Renal: 60-85% (via glomerular filtration and tubular secretion, with acetylation in liver reducing solubility and increasing crystalluria risk). Biliary/fecal: less than 15%. Unchanged drug and acetylated metabolites both excreted.
Renal: 70–80% as unchanged drug; fecal: 10–20% via biliary elimination; minimal hepatic metabolism.
Category D/X
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic